Shares of Danish drugmaker Zealand Pharma fell more than 35% after mid-stage trial results for its experimental weight-loss drug, petrelintide, showed patients lost less weight than expected. The trial, conducted in partnership with Swiss pharmaceutical company Roche, revealed an average weight reduction of 10.7% over 42 weeks, while analysts had anticipated a range between 13% and 20% weight loss [1]. This significant shortfall in expected efficacy prompted Zealand's stock to trade 35% lower, marking its worst day ever and the lowest close since August 2023. Roche's shares also declined by 3% following the news [1].
Zealand Pharma's CEO, Adam Steensberg, addressed the disappointing results in an interview with CNBC, emphasizing that the trial was not optimized for maximum weight loss and that the company is focused on weight maintenance and tolerability rather than achieving the highest possible weight loss. Steensberg criticized the industry's focus on what he called the 'weight loss Olympics,' where companies compete for the largest weight reduction numbers, and argued that real-world patient needs should prioritize staying on medication long-term and minimizing side effects [1].
The weight-loss drug market is highly competitive and lucrative, with estimates suggesting it could be worth as much as $150 billion by 2030. Zealand Pharma is positioning itself to differentiate from competitors like Novo Nordisk and Eli Lilly by focusing on weight maintenance and tolerability. Steensberg expressed confidence that the industry will soon shift its focus toward how patients achieve weight loss and their ability to tolerate medications, rather than just the headline weight loss numbers [1].
Market reactions were swift and negative, with Zealand's shares plummeting and Roche's shares also affected. Analyst expectations were not met, and the trial results have raised questions about Zealand's competitive positioning in the weight-loss drug market [1].
CONCLUSION
Zealand Pharma's disappointing trial results for petrelintide led to a sharp decline in its stock price, reflecting investor concerns about the drug's efficacy compared to market expectations. The company is attempting to shift the industry narrative toward weight maintenance and tolerability, but the immediate market reaction underscores the importance of headline weight loss numbers in this competitive sector. The trial outcome has significant implications for Zealand's future prospects in the lucrative weight-loss drug market.